Investment Q&A

Q: Always looking for return, it seems with the euro almost or at parity it might be an opportunity to put a modest amount of cash into the euro at this time. Do you consider this a good idea or is there a stock or ETF that would do the benefit the same from a future growth point of view?

Peter

Q: Canoo Inc NASDAQ: GOEV does this company have the potential to be another Tesla? Any insider buying and how good is management?

Thank you.

Q: Can you recommend one or more etf's that would provide exposure to the health industry including medical devices, genomics, biotech, big pharma etc. Covered call etf's in these sectors would also be of interest. Thanks

Q: In a question today regarding top health care stocks you mentioned abbivie as one of the top choices but not lly. I know that in the recent past you were strong on lly over abbevie. I bought lly at that time, in fact, and profited quite well from the purchase. Thank you. My question is what made you pinpoint lly as a good prospect earlier on and what brings you to not mention it now in response to the question on top health care stocks?

Q: I am participating in an investment challenge at work. We all pick a portfolio of 1 to 15 CAD or US stocks July 18, 2022 and revalue them October 31, 2023. Whichever portfolio grows the most in CAD wins a cash prize. Can you give me any suggestions of stocks poised to "light it up" over this time period. Note that there is no entry fee so I can invest in extremely risky volatile stocks.

Q: It seems many analysts feel that Health care is a good place to be going into the next 1 to 2 years, do you agree?
Could you name your top 5 Health Care Names, Canada or US?

Thank You

Q: Given Brookfield's backing of SPB, would you be comfortable holding it instead of a much larger company like AQN?

Thanks.

Q: followup to my question from yesterday about dnd. you replied
The Link deal would be highly accretive to earnings, and set DND up for very strong market share and growth. That being said, with the long delays, regulatory issues, and the market, we do not think many investors really think this deal is going to close.
has this been your thinking when you have recently rated, on several occasions, dnd as one of your top growth picks? has your view changed with the apparent demise of the link deal?

Q: CAE looks to have a roughly 50% revenue split from civil aviation and defence - would you consider it comparable to Raytheon without having to be exposed to currency conversions via buy/sells? Thanks

Q: I have to believe there’s value here, especially with Las Vegas so busy and no Macau exposure - what are your thoughts? Thank you

Q: Do you think the natural gas issues in Europe present a real opportunity for PEA (One which they will be able capitalize on)? Is it a reasonable trade or investment now?

Q: I am wondering about the Hamilton ETF offerings and if they may offer a benefit when markets ever "turn the corner". I know it is impossible to time the markets. Could you comment on these few points:
- Will these slightly leveraged products provide extra torque over the base holdings, dollar for dollar, when markets are rising?
- Is slow buying a reasonable option or with leveraged products do we need to look for a clear bottom and changing market sentiment so the leverage doesn't also leverage any ongoing declines?
- Do covered call products provide any downside protection when markets are well off of a growth phase and could slide further?

Thank you!

Q: Hi 5i,
In regards to XEI and VDY ETF's.
I looked at their T3's for the last couple of years using the CDS services site
and found that: XEI seems to consistently have ROC and for VDY it is inconsistent from year to year. These are supposed to be Canadian equity income ETF's so why do they pay a portion of their distribution as ROC? Can you help explain why this might be happening to other ETF's?

Q: Based on your last comments on Pliant therapeutics(PLRX) from May 12, could you please update on those specific comments and on the recent news that made the stock double. Where do you see it going from here? This is what you wrote last time…

Asked by James on May 12, 2021
5I RESEARCH ANSWER:
PLRX has $277M in cash, but only expected revenue of $16M this year. Cash burn was $37M in 2020. 1Q loss of 64 cents per share was 6% worse than estimates; sales of $2.2M were 49% worse than expected. Insiders own 3.5% directly. We do not know management but see no concerns there. There is not much to go on here. As a clinical stage company, performance is going to depend on trial results. It has two main trials (early stage) that will be releasing results later this year. The pipeline is decent but again, early stage. It has been public less than a year, but shares have nearly doubled in that time. There is upside potential for sure, but the future may also be binary based on good/bad trial results.

Q: These six companies comprise my “Small Cap Canadian Technology” holdings. As I like their long term prospects, I am content to hold all of them for their recovery potential over the next few years. However, I would like a second opinion from you: would you agree they are all good companies worth holding, or would you switch any of them out for better quality names? If so, what would be your suggested replacements and why?

Q: Hi, do yo feel they manage to survive or go bankrupt. Greetings Peter.

Q: CSU and BEP.UN are graded A and are your only A grade companies in Canada. What might be an A grade company from the U.S. if you were to grade?

Thx

Q: I'm thinking of switching out of some or all of the above securities to better balance my portfolio. Do you see the potential for a significant bounce on any as negative sentiment or other conditions improve?

Thanks.

Q: Hi, Current Energy Sector weight in 5i Portfolios is as follows:

Balanced : 10.10 % ( SU,ENB)
Income : 7.00 % ( ENB)
Growth : 3.00 % ( KEL,TVE)

Your general recommendation is 7-10% weighting in the Energy Sector, based on individual investor profile/risk/objectives. Could you help understand following:

1. Should we include ENB, as a part of Energy Sector exposure in our personal portfolio like 5i does. Or, ENB should only be considered as Energy Sector exposure for individuals with low/moderate risk tolerance and objectives, suitable for Balanced or Income Portfolio allocation - Not for individuals with Growth as primary Objective.

2. Your general recommended allocation to Energy sector is 7-10%. Do you see current valuations in Energy sector, specially after a recent 15-20% pullback, attractive to increase the weight in Balanced and Growth Portfolio ( specially Growth portfolio - from current 3% ). Any reason Growth portfolio has a low allocation?

In your recent responses, you have made a strong case that the sector still has legs and investors should continue to have a reasonable exposure to the sector. Your recommendation is also well supported by Demand/supply factors, Ukraine and China situation etc. We currently have a 9% weight through CNQ,SU and TOU and an additional 6% through ENB. Just reviewed all 5i portfolios and trying to assess, if there is a need to reduce some positions. Our main objective is income but we are also comfortable to participate, if Sector shows promise of Growth ( of course, with attached risk ). Thanks

Q: can you comment on dnd and acquisition offer being refused but looking for a higher price. how material is the deal to dnd's valuation. what do you see happening.